According to this analyst article from back in March...
Speculative Buy - $8.50 Target Price...
Key statements from the analyst:
- Phase 2 HR+/Her2 Breast Cancer Results
- Company is seeking Co-Development Partners that will allow them to stop using ATM issuances to fund the company.
Pretty important to note, this week is the final week of Q2. Activity we have been provided thus far feels like the tip of the iceberg. Bring on impressive breast cancer results and a huge fundraising deal with big pharma.
Often stocks will put out their best news just ahead of a long weekend. Get the stock rocking. Then everyone talks over the long weekend and you get another bump Up after word spreads.
If this were to occur, today could be that day. Have to think in the very least by the end of July the Brest Cancer results are out and by the end of August the fundraising strategy disclosed.
Despite current healthy volatility, what a wonderful time to be an ONC shareholder! Added 3,000 more shares today. Not a ton, but it's all going to count soon enough! 33k and counting! Show me $10 this summer!!
https://www.cantechletter.com/2023/03/oncolytics-biotech-has-a-big-upside-says-leede-jones-gable/amp/